All In Biotech

Drug Trial Radar · NCT04175847

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

To Evaluate the Safety of RC88 for Injection in Patients With Advanced Malignant Solid Tumors,Multicenter, Open, Multi-cohort Extension of Efficacy and Pharmacokinetic Characteristics Phase I /IIa Clinical Study

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

198

Actual

Start

Apr 14, 2020

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension). The objective of this study was to evaluate safety, tolerability, pharmacokinetic characteristics, and initial efficacy in malignant pleural mesothelioma and MSLN in advanced malignant solid tumors.

Conditions

  • Solid Tumor

Interventions

  • RC88Drug

    Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period. Phase IIa indication exploration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Adverse eventsTime frame: From the day of ICF sign to 28 days after the day of the last treatment
  2. Phase 1 Maximum Tolerated dose of RC88Time frame: 21 days after first treatment.
  3. Phase2Time frame: 24 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.